Clinical trialsCompany release

Oncolytics and Coherus agree toripalimab supply for pelareorep anal cancer study

🇺🇸 Oncolytics Biotech Inc (ONCY) · Thu 12 Nov 2026

Coherus Oncology will supply LOQTORZI for a planned US study pairing it with Oncolytics' investigational oncolytic virus pelareorep in squamous cell anal carcinoma.

Oncolytics Biotech announced on 11 November 2026 that it has signed a clinical supply agreement with Coherus Oncology. Under the deal, Coherus will provide LOQTORZI (toripalimab-tpzi) for a planned study combining the PD-1 inhibitor with pelareorep, Oncolytics' investigational oncolytic virus.

The study is aimed at squamous cell anal carcinoma. It is expected to enrol patients whose disease progressed after first-line treatment with chemotherapy plus a checkpoint inhibitor, a setting where no second-line therapy is currently approved.

The trial is expected to begin in the first quarter of 2027 at a cancer centre in the United States. Oncolytics said it expects to partner with the sponsoring institution. The announcement did not provide further details in the material available, so aspects such as trial design, size and endpoints remain unstated.

As general context, supply agreements of this kind typically allow a developer to run a combination study with a partner's marketed product without a broader commercial collaboration.

What it means for your team

  • Pelareorep remains investigational; the planned study is expected to start in Q1 2027, so no efficacy or safety data are available from it yet.
  • Teams tracking anal cancer should note the stated absence of an approved second-line therapy after chemotherapy plus a checkpoint inhibitor.
  • Trial design, sponsor identity and regulatory submission details have not been disclosed, so watch for the institutional partner announcement.

Company's press release (SEC filing): Oncolytics Biotech Inc ↗

Article written by VigiEye from the official source (Oncolytics Biotech Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →